keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/29445863/use-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-in-austria-from-2008-to-2011-a-retrospective-analysis-of-72-of-the-population
#1
Tanja A Stamm, Berthold Reichardt, Jochen Zwerina, Valentin Ritschl, Valerie Nell-Duxneuner
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6...
February 14, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29422324/abatacept-in-patients-with-rheumatoid-arthritis-and-interstitial-lung-disease-a-national-multicenter-study-of-63-patients
#2
Carlos Fernández-Díaz, Javier Loricera, Santos Castañeda, Raquel López-Mejías, Clara Ojeda-García, Alejandro Olivé, Samantha Rodríguez-Muguruza, Patricia E Carreira, Trinidad Pérez-Sandoval, Miriam Retuerto, Evelin C Cervantes-Pérez, Bryan J Flores-Robles, Blanca Hernández-Cruz, Ana Urruticoechea, Olga Maíz-Alonso, Luis Arboleya, Gema Bonilla, Íñigo Hernández-Rodríguez, Desirée Palma, Concepción Delgado, Rosa Expósito-Molinero, Ana Ruibal-Escribano, Belén Álvarez-Rodríguez, Juan Blanco-Madrigal, José A Bernal, Paloma Vela-Casasempere, Manuel Rodríguez-Gómez, Concepción Fito, Francisco Ortiz-Sanjuán, Javier Narváez, Manuel Moreno, Mireia López-Corbeto, Natalia Mena-Vázquez, Clara Aguilera-Cros, Susana Romero-Yuste, Sergi Ordóñez, Ignacio Villa-Blanco, M Carmen Gonzélez-Vela, Víctor Mora-Cuesta, Natalia Palmou-Fontana, José L Hernández, Miguel A González-Gay, Ricardo Blanco
OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29401118/how-does-abatacept-really-work-in-rheumatoid-arthritis
#3
Michael Bonelli, Clemens Scheinecker
PURPOSE OF REVIEW: The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. RECENT FINDINGS: Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells...
February 3, 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29367417/comparative-cardiovascular-risk-of-abatacept-and-tumor-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-with-and-without-diabetes-mellitus-a-multidatabase-cohort-study
#4
Eun Ha Kang, Yinzhu Jin, Gregory Brill, Jennifer Lewey, Elisabetta Patorno, Rishi J Desai, Seoyoung C Kim
BACKGROUND: We examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus (DM). METHODS AND RESULTS: We conducted a cohort study of patients with rheumatoid arthritis who newly started abatacept or TNF inhibitors using claims data from Medicare and MarketScan. The primary outcome was a composite cardiovascular end point of myocardial infarction (MI), stroke/transient ischemic attack, and coronary revascularization...
January 24, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29358281/visualising-the-interaction-of-cd4-t-cells-and-dcs-in-the-evolution-of-inflammatory-arthritis
#5
Catriona T Prendergast, Agapitos Patakas, Shaima Al-Khabouri, Claire L McIntyre, Iain B McInnes, James M Brewer, Paul Garside, Robert A Benson
OBJECTIVES: Successful early intervention in rheumatoid arthritis (RA) with the aim of resetting immunological tolerance requires a clearer understanding of how specificity, cellular kinetics and spatial behaviour shape the evolution of articular T cell responses. We aimed to define initial seeding of articular CD4+ T cell responses in early experimental arthritis, evaluating their dynamic behaviour and interactions with dendritic cells (DCs) in the inflamed articular environment. METHODS: Antigen-induced arthritis was used to model articular inflammation...
January 22, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29329602/abatacept-used-in-combination-with-non-methotrexate-disease-modifying-antirheumatic-drugs-a-descriptive-analysis-of-data-from-interventional-trials-and-the-real-world-setting
#6
Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E Voll, Yedid Elbez, Christiane Rauch
BACKGROUND: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modifying antirheumatic drug (csDMARD) combinations with abatacept are scarce. METHODS: In this post-hoc exploratory analysis, efficacy and safety data were extracted from abatacept RA studies in which combination with csDMARDs other than MTX was permitted: three interventional trials (ATTAIN, ASSURE, and ARRIVE) and one real-world study (ACTION)...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29303709/cost-effectiveness-of-early-treatment-of-acpa-positive-rheumatoid-arthritis-patients-with-abatacept
#7
Aljoscha S Neubauer, Christof Minartz, Kirsten H Herrmann, Christoph G O Baerwald
OBJECTIVES: Studies have reported that the presence of elevated anti-citrullinated protein antibodies (ACPA)/RF levels, together with joint erosions, is associated with higher disease burden in terms of disability and mortality in rheumatoid arthritis (RA). Abatacept has been shown to be effective in this patient population with favourable comparative data against adalimumab. However, few studies have investigated the cost-effectiveness of abatacept in this population to similar treatments such as TNFs...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#8
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29259723/effects-of-ctla4-ig-on-human-monocytes
#9
Toshihiro Tono, Satoko Aihara, Takayuki Hoshiyama, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata
Background: Abatacept, a CTLA4-Ig fusion protein attenuates T cell activation by inhibiting the CD80/86-CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid arthritis (RA). Although some studies have disclosed the in vitro effects of this biological agent on the immune-competent cells, the precise mechanisms of action in RA still remain unclear. The current studies were therefore undertaken to explore the effects of abatacept on monocytes in detail...
2017: Inflammation and Regeneration
https://www.readbyqxmd.com/read/29237621/patient-characteristics-influence-the-choice-of-biological-drug-in-ra-and-will-make-non-tnfi-biologics-appear-more-harmful-than-tnfi-biologics
#10
Thomas Frisell, Eva Baecklund, Karin Bengtsson, Daniela Di Giuseppe, Helena Forsblad-d'Elia, Johan Askling
OBJECTIVES: With the wide range of biological disease-modifying anti-rheumatic drugs (bDMARDs) available for treating rheumatoid arthritis (RA), and limited evidence to guide the choice for individual patients, we wished to evaluate whether patient characteristics influence the choice of bDMARD in clinical practice, and to quantify the extent to which this would bias direct comparisons of treatment outcome. METHODS: Register-based study of all Swedish patients with RA initiating necrosis factor inhibitor (TNFi), rituximab, abatacept or tocilizumab in 2011-2015 as their first bDMARD (n=6481), or after switch from TNFi as first bDMARD (n=2829)...
December 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29205926/a-retrospective-review-of-the-persistence-on-bdmards-prescribed-for-the-treatment-of-rheumatoid-arthritis-in-the-australian-population
#11
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
AIM: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage. METHOD: RA patients, from the 10% Australian Medicare random sample, aged ≥18 for whom bDMARDs were dispensed were included. Individual sub-cutaneous (SC) anti-tumor necrosis factor-α (anti-TNFα) agents were combined as they were equivalent...
December 5, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29205904/dosing-down-and-then-discontinuing-biologic-therapy-in-rheumatoid-arthritis-a-review-of-the-literature
#12
REVIEW
Der-Yuan Chen, Chak Sing Lau, Bassel Elzorkany, Ping-Ning Hsu, Sonja Praprotnik, Radu Vasilescu, Lisa Marshall, Lyndon Llamado
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab...
February 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29204683/wide-difference-in-biologics-usage-and-expenditure-for-the-treatment-of-patients-with-rheumatoid-arthritis-in-each-prefecture-in-japan-analyzed-using-national-database-of-health-insurance-claims-and-specific-health-checkups-of-japan
#13
Yasuyuki Kamata, Seiji Minota
To analyze the biologics usage and expenditure for the treatment of patients with rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open database, the Ministry of Health, Labour and Welfare of Japan disclosed; in Oct 2016, the data of the top 30 most-frequently prescribed drugs during a 1-year period from April 2014 to March 2015 in each prefecture in Japan, along with the patients' age and sex. Seldom-used drugs were excluded. We picked up only biologics for the present study...
December 5, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29197108/refining-a-claims-based-algorithm-to-estimate-biologic-medication-effectiveness-and-cost-per-effectively-treated-patient-with-rheumatoid-arthritis
#14
Ryan A Popp, Karen Rascati, Matthew Davis, Ujas Patel
BACKGROUND: Claims data generally lack information on clinical outcomes. However, a validated, claims-based algorithm for estimating effectiveness of biologic agents in treating rheumatoid arthritis (RA) has recently been developed and applied to various databases. OBJECTIVES: The objectives of the study were to implement a claims-based algorithm in a large nationwide database to estimate medication effectiveness and cost for patients with RA using biologic disease-modifying antirheumatic drugs (DMARDs) and to assess the effect of eliminating one criterion from the algorithm on results...
December 1, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29177081/impact-of-gender-on-the-response-and-tolerance-to-abatacept-in-patients-with-rheumatoid-arthritis-results-from-the-ora-registry
#15
Cynthia Nourisson, Martin Soubrier, Aurélien Mulliez, Athan Baillet, Thomas Bardin, Alain Cantagrel, Bernard Combe, Maxime Dougados, René-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Philippe Ravaud, Jacques-Eric Gottenberg, Xavier Mariette, Anne Tournadre
Objective: The impact of gender on the response and tolerance to abatacept was assessed in a large prospective cohort during 2 years of follow-up. Methods: From the 1017 patients included in the Orencia and Rheumatoid Arthritis registry, disease activity was assessed at baseline, 6, 12 and 24 months. The relationship between the European League Against Rheumatism (EULAR) response, Disease Activity Score 28 (DAS28) remission, rate of adverse events and gender was explored in multivariate analysis...
2017: RMD Open
https://www.readbyqxmd.com/read/29161466/treating-early-undifferentiated-arthritis-a-systematic-review-and-meta-analysis-of-direct-and-indirect-trial-evidence
#16
Maria A Lopez-Olivo, Voke Kakpovbia-Eshareturi, Jude des Bordes, Andrea Barbo, Robin Christensen, Maria E Suarez-Almazor
OBJECTIVE: We undertook a systematic review and meta-analysis of direct and indirect trial evidence to evaluate the efficacy of treatments for patients with undifferentiated arthritis (UA). METHODS: We searched four electronic databases from inception to January 2016, clinicaltrials. gov, and bibliographies of relevant articles. Two reviewers independently screened and evaluated the studies. The primary outcome was development of rheumatoid arthritis (RA). RESULTS: Nine studies were included...
November 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29146547/a-gene-module-associated-with-dysregulated-tcr-signaling-pathways-in-cd4-t-cell-subsets-in-rheumatoid-arthritis
#17
Shuji Sumitomo, Yasuo Nagafuchi, Yumi Tsuchida, Haruka Tsuchiya, Mineto Ota, Kazuyoshi Ishigaki, Shinichiro Nakachi, Rika Kato, Keiichi Sakurai, Norio Hanata, Shoko Tateishi, Hiroko Kanda, Akari Suzuki, Yuta Kochi, Keishi Fujio, Kazuhiko Yamamoto
We analyzed the transcriptome of detailed CD4(+) T cell subsets including them after abatacept treatment, and examined the difference among CD4(+) T cell subsets and identified gene sets that are closely associated disease activity and abatacept treatment. Seven CD4(+) T cell subsets (naive, Th1, Th17, Th1/17, nonTh1/17, Tfh and Treg) were sorted from PBMCs taken from 10 RA patients and 10 healthy controls, and three RA patients donated samples before and 6 months after abatacept treatment. Paired-end RNA sequencing was performed using HiSeq 2500...
November 13, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29146040/-effectiveness-therapeutic-maintenance-and-reasons-for-stopping-tocilizumab-tcz-a-retrospective-and-monocentric-study-in-88%C3%A2-patients-followed-for-rheumatoid-arthritis-ra-at-the-reims-university-hospital
#18
Clément Chopin, Loïc Pauvele, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon
OBJECTIVE: Study the therapeutic maintenance, efficacy and reasons for tocilizumab stop in daily practice. PATIENTS AND METHODS: A monocentric, retrospective study of patients treated for rheumatoid arthritis who received at least one TCZ infusion between January 2009 and December 2015. Therapeutic maintenance was evaluated using the Kaplan-Meier method. The efficacy of TCZ was measured by DAS28 and the EULAR response. Reasons for stopping and new treatment lines were also collected...
October 18, 2017: Thérapie
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#19
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
December 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29102157/the-ultrasound-clinical-arthritis-activity-us-clara-index-properties-of-a-new-composite-disease-activity-index-for-rheumatoid-arthritis
#20
Fausto Salaffi, Marco Di Carlo, Florenzo Iannone, Anna Laura Fedele, Oscar Massimiliano Epis, Raffaele Pellerito, Rosario Foti, Giuseppe Passiu, Leonardo Punzi, Federica Furini, Piercarlo Sarzi-Puttini, Antonio Carletto, Elisa Gremese, Giovanni Lapadula, Gianfranco Ferraccioli
OBJECTIVE: To assess validity, responsiveness and interpretability of the UltraSound-CLinical ARthritis Activity (US-CLARA) index in patients with rheumatoid arthritis (RA). METHODS: In this longitudinal study were involved RA patients starting treatment with abatacept. Subjects were followed along three visits in the first 6 months of therapy and underwent a comprehensive clinimetric evaluation. Validity was explored correlating the baseline scores and the cumulative inflammatory burden of the US-CLARA with the other composite indices applied...
September 28, 2017: Seminars in Arthritis and Rheumatism
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"